Publications

Monovalent Antibody Design and Mechanism of Action of Onartuzumab, a MET Antagonist with Anti-tumor Activity as a Therapeutic Agent

Merchant M, et al., 110(32), E2987-96, Proc Natl Acad Sci U S A, 2013

This paper describes the development and characterization of onartuzumab, an E. coli-derived, humanized, and affinity-matured monovalent monoclonal antibody against MET. The Octet RED system was used for binding measurements of wild-type and mutants of MET Sema-PSI to onartuzumab. The onartuzumab Fab was biotinylated and loaded onto Streptavidin biosensors for binding studies. Rates of association, dissociation, and binding affinities were reported.

Read More